<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" type="text/css" href="css/style-manual.css">
    <link rel="stylesheet" href="https://www.w3schools.com/w3css/4/w3.css">
    <script src="js/script.js"></script>
</head>
<body>
	<div class="bodyDiv">
    <div class="w3-container w3-center w3-animate-left">
        <h2 class="mango">Objective and Action</h2>
    </div>
<b>Allertin:</b><br>
<b>Objective for 4th QTR 2023:</b><br>
• 1 Cr./ Monthly Target<br>
. Establish Allertin as the only anti-histamine having no sedation & the drug of choice for Allergic Rhinitis & Chronic Urticaria.<br>
• Each MPI must ensure PCPM TK. 8,000/-within 4th QTR. Current PCPM is Tk. 5,644/-<br>

<b>Actions to be taken in 4th QTR 2023
:</b><br>
• Number of Zero seller & MPI bellow 60% Ach. need to be decreased from each region.<br>
• Allertin 4P Share: According to 4P we are lagging behind to grab Market share. So need to be aggressive in the market
and ensure maximum 4P share which will ultimately impact on your sale.<br>
• Please give special focus on Eye & ENT specialist to ensure maximum Rx of Allertin.<br><br>

<b>Arokast:</b><br>
<b>Objective for 4th QTR 2023:</b><br>
• In the 4th QTR, we want to achieve 2 cr. tk sales of Arokast in average. In that case, we have to ensure a significant growth of Rx & sales in every territory<br>
• Each MPI ensure 3 loyal Rxers & 1 casual one<br>

<b>Actions to be taken in 4th QTR 2023 :</b><br>
Develop new prescribers from ENT and Medicine specialist doctors.<br>
• Snacks program from Arokast-Allertin to develop ENT departments of medical colleges.<br>
• Please give emphasis on the Indoor units of the ENT and Medicine department.<br>
• Try to work with the 4P & MSP doctor to ensure we achieve the top rank in the 4P & MSP.<br><br>
	
<b>Clonipres:</b><br>
<b>Objective for Clonipres ER & Clonipres in 4th QTR 2023:</b><br>
• 1 Cr./Monthly Target( Now 58 Lac)<br>
• Establish Clonipres ER as the safer non-stimulant approach for ADHD in psychiatrist, neurologist and peadiatric doctor.<br>
• Establish Clonipres as the non-hormonal preparation to treat hot flash (to Gynaecologist) and the best drug to treat hypertensive urgency (to Medicine Sp.)<br>
• Make 5 loyal doctors/Al for Clonipres & ensure at least 5 Rx daily in NPL e-Life from them
Now.<br>

<b>Actions to be taken for Clonipres ER & Clonipres in 4th QTR 2023:</b><br>
• Promote right indication in right specialty with following indication wise statement-is-<br>
<b>Clonipres 0.1:</b><br>
Psychiatrist & Pediatrician
Neurologist.<br>
A safer non-stimulant approach for ADHD<br>
Clonipres:<br>
Gynaecologist<br>
The only non-hormonal drug to treat hot flash<br>
Medicine Sp.<br>
Add on therapy for better control of hypertension & hypertensive urgency.<br>
<b>Clonipres ER 0.1:</b><br>
• Arrange CME/RTM of Clonipres ER at every psychiatry & neuro
department of major institution<br>
• Ensure a learning session on Clonipres ER and memorize 1 min
detailing of Clonipres ER.<br>
Clonipres:<br>
• Promote Clonipres vigorously to policy doctor as shareholder
doctors will get Tk. 97.2/Rx<br>
• Convert every Tibolone and HRT prescriber to Clonipres<br><br>
	
<b>Curafin:</b><br>
<b>Objective:</b><br>
1.3 Cr./ Monthly.<br>

<b>Actions to be taken in 4th QTR 2023
:</b><br>
• Combination of Itraconazole & Amorolfine shows 100% synergistic action against many trichophyton spp.<br>
• So please promote Itracon & Curafin together by our new literature. For more information, please read our model detailing
Itracon & Curafin.<br><br>
	
<b>***Dextac:</b><br>
<b>Objective for 1st QTR 2024:</b><br>
• Our Objective to make Dextac 60 Cr. Taka brand in 2024_ 5 Cr/month.<br>
• Month-wise objective: Jan: 3.9 Cr. Feb: 4.2 Cr. Mar: 4.5 Cr.<br>
• Each MPI must ensure PCPM Tk.50,000/- within 1st QTR.<br>
Current PCPM is Tk. 33,000/-<br>
• 4P & MSP objective to be No-1<br>

<b>Actions to be taken in 1St QTR 2024
:</b><br>
• Do not promote Vontac to any single Dextac prescriber at any situation. There are so many non-Dextac prescribers. Promote Vontac to them. Mind it we also need to create new Dextac prescribers.<br>
• Ensure chemist growth of Dextac in every month.<br>
• Convert DEXILEND Rxer to Dextac 

Actions to be taken in 1st QTR 2024
• Focus on Gyne Doctors. Ensures at least 2 Gyne Doctors per MPI<br>
• Ensure chemist growth of Dextac in every month.<br>
• Convert Dexilend & Dexlan Rxer to Dextac<br>
• Ensures regular Rx from our Regular Prescribers (Medicine, Ortho, Gastro & GP)<br>
• New Year Campaign with Customized Diary, Institute program (New year)<br>
• Valentine Campaign in February & D. Pad design of International Mother Language Day<br>
• Children Art Competition on Independence Day in March


<br><br>
	
<b>Duracef:</b><br>
Objective for 4th QTR 2023:</b><br>
• 2.5 Cr./ Monthly Target_ Now 1.9 Cr.<br>
• Establish Duracef as the drug of choice for Respiratory Tract Infections (RTIs) in paediatrician, for prophylaxis in surgeries and for Bronchitis/Pneumonia/Typhoid fever in medicine.<br>
• Establish Duracef-Max as a choice of drug among all paediatricians.<br>
• Ensure 4P share 6% in every area
<br>

<b>Actions to be taken in 4th QTR 2023
:</b><br>
• Focus on pulmonologists & medicine specialty for Rx of Duracef in RTI as patients are increased significantly at doctor's chamber.<br>
• Follow strictly the right indication in right specialty<br>
• Promote vigorously in Surgery department as a switch therapy. Every discharge unit must be focused.<br>
• Make 1 loyal prescriber/MPI who will give 15 Rx per week.<br>
• Utilize snacks program from Duracef to increase the Rx.<br><br>

<b>Esona:</b><br>
<b>Objective for 4th QTR 2023:</b><br>
• 1 Cr. brand within Nov 23 (Need 35 lac growth)
• Ensure 3.5% Rx share in 4P (currently at 2.75%, 4P Sep) for Esona within Nov'23<br>
• Convert prescribers of Xenole (Square) and Progesic (Incepta) to Esona prescribers.<br>

<b>Actions to be taken in 4th QTR 2023
:</b><br>
• Ensure a regular visit to the Orthopedics, Rheumatology, Physical medicine & GPs.<br>
• Develop 1 core Doctor/MPI and ensure at least 2 Rx/MPI/Day for Esona in every territory.<br>
• World Arthritis day celebration<br>
<br><br>

<b>***Fixcef Plus:</b><br>
<b>Objective for 1st QTR 2024:</b><br>
Target 3.5 Cr(Now 2.6 Cr)<br>
Increase 4P share by about 100% in every territory. (eg. If you have a 4P share of 1%, make it 2%)<br>

<b>Actions to be taken in 1st QTR 2024:</b><br>
• 1st quarter is the months of the winter season when lots of <b>ENT</b> infections occur. Fixcel Plus is the 1st 
choice of drug for this disease. So promote it to all ENT specialists to maximize the seasonal benefit.<br>

•Provide "The Combo Box containing Diary, Calendar & Pen" to Fixcel Plus doctor only & ensure maximum 
benefit from it. Remember one thing. "Don't use this gift to any other doctor except Fixcef Plus prescribers"

Celebrate the "New Year Campaign" with the active participation of target doctors & take maximum benefit from it.<br>

•Focus on <b>dental</b> doctors & promote Fixcef Plus to every dentist.<br>

•Ensure maximum benefit from those doctors <b>who get special gifts</b> through regional head (The regional head gets 10 to 15 gifts from Fixcef Plus in every month for some special doctors)

<br><br>
	
<b>***Itracon:</b><br>
<b>Objective for 1st QTR 2024:</b><br>
• Objective 10cr/Monthly<br>
• Cover all dermatologist & pediatricians.<br>
• Establish Itracon OS as the drug of choice in oral thrush for pediatricians<br>
• Everyday send 10 Rx/MPI in NPL-eLife, do not miss it.<br>
• 55% Rx share in 4P & MSP nationally within 1st QTR.<br>

<b>Actions to be taken in 1st QTR 2024:</b><br>
• Establish Itracon as a first line treatment for all types of superficial fungal infections.<br>
• Please cover Skin dept. of all medical colleges, your major institute and ensure maximum Rx of Itracon<br>
• Square, Uniderma, Opsonin & Beacon have recently launched Itraconazole (Itra 200 mg, Itrader 100 mg & Itrazen 100
mg Cap). As we know that Square, Uniderma & Beacon is very strong in derma portfolio & in Doctor front.<br>
So please be more aggressive to retain our share in the market.<br>
• Each region please ensure at least 2 CMEs in the skin department of medical colleges, Sadar hospitals & Upazila 
health complexes.
<br><br>

<b>***Kindical:</b><br>
<b>Objective for 1st QTR 2024:</b><br>
• 3 Cr within 1 QTR 2024<br>
• To establish Kindical as the choice of drug to gynaecologists for the deficiency of Calcium and Vitamin D of 
pregnant, lactating, and postmenopausal women<br>
• Achieve 4P Rx share 7% within 1st QTR 2024<br>

Actions to be taken in 1st QTR 2024:</b><br>
• Develop <b>2 loyal gynecologists/MPI</b><br>
• Don't replace the prescribers of Kindical with other products<br>
• Develop at least<b>3 orthopedics/Al(new)</b><br>
• New Year Celebration: Calendar, Cake, Tissue and Institution campaign<br>
• Vigorous promotion to all gynaecologists and orthopaedics
<br><br>

<b>Loxodol:</b><br>
<b>Objective for 4th QTR 2023:</b><br>
• Establish Loxodol as a drug of choice to orthopaedics as a pain killer.<br>
• Make Loxodol 1 crore within Nov'23<br>
• Develop 02 Doctors/MPI within Nov'23<br>

<b>Actions to be taken in 4th QTR 2023
:</b><br>
• Arrange CME for at least 1/ month /region along with Malifa.<br>
• Develop policy doctors as Loxodol prescribers. (Profit Share: Loxodol 4: 0.9 Tk. /Tab. & Loxodol 8: 2.80 Tk./Tab.)<br>
• Promote to all dentists, orthopedics, physical medicine, pain sp.<br>
• Promote Loxodol 8 instead of Loxodol 4 because Loxodol 8 has higher profit share & higher price than Loxodol 4.<br><br>

<b>Phoscon:</b><br>
<b>Objective for 4th QTR 2023:</b><br>
• Target 1 cr. Within Oct 23<br>
• Tell every Phoscon doctor that Phoscon is first time in Bangladesh<br>
• Establish Phoscon as a drug of choice for the treatment of Hyperphosphatemia &
Anemia in CKD<br>

<b>Actions to be taken in 4th QTR 2023
:</b><br>
• Ensure visit to all nephrologists in your territory & ensure at least 90% Rx from them<br>
• We have been providing the Phoscon doctor list to regional heads. Please ensure visiting them.
<br>
• Arrange at least 1 CME/Month/Region at Nephrology department of medical colleges and dialysis centers<br><br>

<b>Pregan ER & N-bion:</b><br>
<b>Pregan ER:</b><br>
<b>Objective for 4th QTR 2023:</b><br>
• 1 Cr. Brand within 4th QTR<br>
• No.1 Brand in 4P.<br>
• To regain & hold the no. 1 position throughout the 4th QTR in 4P's Pregabalin ER/CR category. (Current position fluctuates between 2nd & 3rd)<br>
<b>N-bion:</b><br>
• 1 Cr. Brand within 4th QTR(Now 85 lac/ month).<br>
• 5% 4P share with in 4th QTR.<br>
	
<b>Actions to be taken in 4th QTR 2023
:</b><br>
• Co-promote Pregan ER & N-bion in the same call.<br>
• Develop 10 Loyal Doctors for Pregan ER & 10 Loyal Doctors for N-bion at every region according to the most potential doctors list given from SBMD. Every Regional Head will get 10 exclusive gifts from both Pregan ER & N-bion in every month.<br>
• Snacks program will be conducted in some selected orthopedic departments of targeted institutions.<br>
• New campaign will be conducted
</div>
<footer>
    <p>© 2024 Md. Nurullah. All rights reserved.</p>
</footer>
</body>
</html>